Overview:

Oral selective estrogen receptor degraders (SERDs) and targeted combination strategies are reshaping the treatment landscape for HR+/HER2- metastatic breast cancer. Following progression on CDK4/6 inhibitor plus endocrine therapy, clinicians now have multiple therapeutic options, including oral SERDs as monotherapy and in combination with CDK4/6 inhibitors, PI3K/AKT/mTOR inhibitors, and other targeted agents. As these therapies become available, it is vital for clinicians to stay current on the evolving clinical efficacy data, understand the distinctions between available agents, and recognize the unique safety profiles and toxicity management strategies for each approach.

This program brings together expert faculty to discuss the latest advances and enable the integration of oral SERDs and emerging combination strategies into HR+/HER2- metastatic breast cancer care. Through interactive, case-based discussions between academic and community oncology colleagues, participants will gain practical insights and strategies to navigate complex treatment selection and sequencing decisions, differentiate between monotherapy and combination approaches based on patient-specific factors, apply real-world evidence alongside clinical trial data, and proactively manage treatment-related adverse events to optimize patient outcomes.

Learning Objectives:

Upon completion of this activity, learners will be better able to:

• Apply real-world evidence to inform second-line treatment selection for patients with HR+/HER2− metastatic breast cancer following progression on CDK4/6 inhibitor therapy.
• Differentiate between oral SERDs and emerging targeted combinations based on efficacy, safety, and patient-specific factors.
• Evaluate the clinical utility of ctDNA surveillance for ESR1 mutations in patients responding to first-line therapy.
• Integrate patient-reported outcomes and quality-of-life considerations when selecting between monotherapy and combination treatment strategies.

Target Audience:

This educational program is primarily directed toward a global audience of community-based medical oncologists, surgical oncologists, advanced practice providers, nurses, and other healthcare providers involved in the treatment of metastatic breast cancer.

Accreditation/Credit Designation:

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour. 

Have a question for the PER® team?

Oncology Inquiries: onc-info@gotoper.com

Eye Care Inquiries: eye-info@gotoper.com

Multispecialty Inquiries: multi-info@gotoper.com